HC Wainwright & Co. Reinstates Buy on Crinetics Pharmaceuticals, Maintains $35 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao reinstated a Buy rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and maintained a $35 price target.
June 20, 2023 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Crinetics Pharmaceuticals (CRNX) receives a Buy rating and a $35 price target from HC Wainwright & Co. analyst Douglas Tsao.
The reinstatement of the Buy rating and maintenance of the $35 price target by HC Wainwright & Co. analyst Douglas Tsao indicates a positive outlook for Crinetics Pharmaceuticals. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100